Candel Therapeutics, Inc.
CADL
$4.79
$0.030.63%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -32.19% | 52.12% | -170.49% | 25.90% | -31.54% |
| Total Depreciation and Amortization | 0.00% | -1.61% | -0.80% | 0.80% | 1.63% |
| Total Amortization of Deferred Charges | -16.13% | -15.07% | -12.05% | -3.49% | 3.61% |
| Total Other Non-Cash Items | 147.06% | -80.87% | 1,250.66% | -35.04% | 387.68% |
| Change in Net Operating Assets | -11.97% | 91.38% | 126.22% | -205.32% | 250.95% |
| Cash from Operations | 11.55% | -6.05% | 26.55% | -13.69% | 15.74% |
| Capital Expenditure | -- | 100.00% | 14.29% | 85.11% | 54.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 14.29% | 74.07% | 73.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | -49.97% | -- | -- |
| Issuance of Common Stock | 2,160.31% | -6.03% | 978.88% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5,380.80% | -13.78% | 254.98% | -937.19% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,858.50% | -14.96% | 56.09% | -28.14% | 15.05% |